England is the first country in the world to make GSK's anti-BCMA drug Blenrep available to patients with the haematological ...

GSK is putting the finishing touches on its case for antibody-drug conjugate Blenrep with a key progression-free survival ...

Lilly announced a definitive agreement to acquire private biotech, SiteOne Therapeutics, which will add novel non-opioid medicines for pain management to its pipeline portfolio. SiteOne Therapeutics ...

A final decision from the FDA is expected on July 23, 2025. Blenrep combinations were approved in the United Kingdom and Japan in April and May 2025, respectively. Besides the United States and ...

Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion recommending approval for the Blenrep (belantamab mafodotin) combination therapy to treat relapsed or refractory ...

This latest announcement follows the recent approvals of Blenrep combos by regulatory agencies in Japan and the UK. The pivotal Phase III trials, DREAMM-7 and DREAMM-8, have demonstrated superior ...

Blenrep, in combination with bortezomib plus dexamethasone ... approvals by the UK Medicines and Healthcare products Regulatory Agency in April and by Japan’s Ministry of Health, Labour and Welfare ...

Last month, Blenrep earned an approval in the U.K. Then earlier this week, officials in Japan endorsed the GSK regimen. The FDA has a target date of July 23 to decide on the Blenrep combo.

Blenrep, in combination with bortezomib plus ... UK Medicines and Healthcare products Regulatory Agency in April and by Japan’s Ministry of Health, Labour and Welfare earlier this month.

Blenrep is a monoclonal antibody used for the ... U.K.'s Medicines and Healthcare products Regulatory Agency in April and Japan's Ministry of Health, Labour and Welfare earlier this month, it ...

GSK plc has received approval for Blenrep combinations from Japan's Ministry of Health, Labour and Welfare (MHLW) for the treatment of adults with relapsed or refractory multiple myeloma. The approval ...